Browsing by Subject "Etoposide"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Effect of chemotherapy on pulmonary epithelial permeability in lung cancer
    (2000) Sayit E.; Aktoǧu S.; Ertay T.; Çapa G.; Erkmen G.; Özbilek E.; Büyükşirin M.; Durak H.
    The aim of this study is to investigate the effect of one-course chemotherapy on the pulmonary epithelial permeability. Eighteen patients (18 male; mean age: 59 ± 10 years) with lung cancer (11 non-small cell, 7 small cell) inhaled 40 mCi (1,480 MBq) 99mTc-diethylenetriaminepentaacetic acid (DTPA). Thirty images of 1-min duration were acquired from posterior projection. The first 7 min of the decay-corrected time activity curves were used to calculate lung clearance half-time. Clearance half-times of 99mTc-DTPA from the peripheral regions of the lungs were 42 ± 19 min before and 56 ± 34 min after chemotherapy (p = 0.009); from the central regions, clearance half-times were 112 ± 94 min before and 160 ± 125 min after chemotherapy (p = 0.005). This decrease in clearance rate might be related to decreasing mucociliary clearance rate due to the toxic effect of the chemotherapy regimen on cilia movement and/or mucus structure. 99mTc-DTPA radioaerosol study can be used to monitor the toxic effects of chemotherapy on the pulmonary epithelium and possibly on mucociliary function. (C) 2000 Elsevier Science Inc.
  • No Thumbnail Available
    Item
    Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey
    (2008) Demiral A.N.; Alicikus Z.A.; Işil Ugur V.; Karadogan I.; Yöney A.; Andrieu M.N.; Yalman D.; Pak Y.; Aksu G.; Özyigit G.; Özkan L.; Kilçiksiz S.; Koca S.; Çaloǧlu M.; Yavuz A.A.; Başak Çaǧlar H.; Beyzadeoǧlu M.; Iǧdem S.; Serin M.; Kaplan B.; Koç M.; Korkmaz E.; Karakoyun-Çelik O.; Dinçer S.; Kinay M.
    Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were "≥ IB" disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. © 2008 Elsevier Inc. All rights reserved.